AOK PLUS - THE HEALTH INSURANCE FOR SAXONY AND THURINGIA has floated a tender for Degree of Non-exclusive Drug Discount Agreements According to § 130a Para. 8 Sgb V in the Way of a So-called Open-house Model for Active Substance Fusidic Acid (atc Code to Who: D06ax01). The project location is Germany and the tender is closing on 31 Mar 2024. The tender notice number is 037469-2022, while the TOT Ref Number is 62439688. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Expired Tender

Procurement Summary

Country : Germany

Summary : Degree of Non-exclusive Drug Discount Agreements According to § 130a Para. 8 Sgb V in the Way of a So-called Open-house Model for Active Substance Fusidic Acid (atc Code to Who: D06ax01)

Deadline : 31 Mar 2024

Other Information

Notice Type : Tender

TOT Ref.No.: 62439688

Document Ref. No. : 037469-2022

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : AOK PLUS - THE HEALTH INSURANCE FOR SAXONY AND THURINGIA
Address: Augustinerstraße 38
Town: Erfurt
Nuts Code: DEG - Thuringia
Postal Code: 99084
Contact Point: Corporate Governance Business Unit Corporate Contracting Office
Phone: +49 8001059080066
Germany
Email :vergabestelle@plus.aok.de
URL :https://plus.aok.de/

Tender Details

Document Type: Contract Notice

Title: Degree of non-exclusive drug discount agreements according to § 130a para. 8 SGB V in the way of a so-called open-house model for active substance fusidic acid (ATC code to WHO: D06AX01)

Reference Number: 21/2022-Oh

Contract Type: Supplies

Description: The subject of this publication is the conclusion of not exclusive discount agreements according to § 130a para. 8 SGB V via drug with the active substance Fusidic acid (ATC code according to WHO: D06AX01). The contract is carried out as part of a so-called Open-House model, d. H. A conclusion of the contract is open within the participation period all interested pharmaceutical companies, provided that they meet and accept the participation requirements. This has the consequence that individual contract negotiations are not led and a (delivery) exclusivity is not given. It should be noted that the amount of purchase is unknown, as it depends on demand and the development of the insurance of the insurance, from the prescription behavior of physicians and the dispensing and storage behavior of public pharmacies. Minimum collection quantities are not considered to be ...

Documents

 Tender Notice